Table 2.
Disease activity, anxiety, and depression levels in SLE patients at inclusion and follow-up visits.
| Baseline 1 | Follow-Up | p-Value 2 | |
|---|---|---|---|
| SLEDAI-2K 3 | 6.0 (4.0) | 4.0 (2.0) | 0.001 |
| 0 | 0 (0.0%) | 5 (12.5%) | |
| 1–4 | 14 (35.0%) | 22 (55.0%) | |
| 5–8 | 22 (55.0%) | 13 (32.5%) | |
| ≥9 | 4 (10.0%) | 9 (0.0%) | |
| HADS-Anxiety | 11.0 (7.8) | 11.0 (5.5) | 0.964 |
| Normal (≤7) | 12 (30.0%) | 8 (20.0%) | |
| Mild (8–10) | 7 (17.5%) | 9 (22.5%) | |
| Moderate (11–14) | 11 (27.5%) | 13 (32.5%) | |
| Severe (≥15) | 10 (25.0%) | 10 (25.0%) | |
| HADS-Depression | 8.0 (4.8) | 8.0 (6.8) | 0.463 |
| Normal (≤7) | 19 (47.5%) | 19 (47.5%) | |
| Mild (8–10) | 12 (30.0%) | 13 (32.5%) | |
| Moderate (11–14) | 6 (15.0%) | 7 (17.5%) | |
| Severe (≥15) | 3 (7.5%) | 1 (2.5%) |
1 Data are presented as median (interquartile range) or no. (%). 2 Wilcoxon Signed Rank Test. 3 SLE Disease Activity Index-2K.